Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
A synthetic purine nucleoside analog consisting of a 6-methylpurine base attached to a deoxy-alpha-L-talofuranose sugar. It is classified as an experimental small molecule and has not been approved for clinical use. The compound is structurally related to cytotoxic adenine analogs and may act by interfering with nucleic acid synthesis or function; however, its precise mechanism of action in biological systems has not been fully characterized[1][2][4]. No clinical indications or approved uses are reported.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 9-(6-deoxy-alpha-L-talofuranosyl)-6-methylpurine.